Drugs / Nap-paclitaxel
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06576921 Background | Nov 2024 → Aug 2026 overdue | gastric neoplasm | Xijing Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nap-paclitaxel | “Nap-paclitaxel, 260 mg/m2 intravenously on days 1;” NCT06576921 ↗ |
| Route | Intravenous | “Nap-paclitaxel, 260 mg/m2 intravenously on days 1;” NCT06576921 ↗ |